CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

(2019) Tania Jain et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

(2019) Brad S. Kahl et al.   CLINICAL CANCER RESEARCH

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

(2018) W Jurczak et al.   ANNALS OF ONCOLOGY

ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies

(2018) Francesca Zammarchi et al.   BLOOD

Management of relapsed/refractory DLBCL

(2018) Clémentine Sarkozy et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation

(2014) Mehdi Hamadani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD